summary
? Optiscan signs a know-how agreement with Mayo Clinic in the U.S. to jointly develop a new endoscopic imaging system
The two companies will collaborate on the development of technologies for robotic surgery
Co-development and clinical testing will begin in the near future, with an initial focus on robotic-assisted breast cancer surgery
? Mayo Clinic will benefit financially from Optiscan's technology
MELBOURNE, Australia--(BUSINESS WIRE)--Optiscan Imaging Limited (ASX:OIL) ("Optiscan" or the "Company") is pleased to announce that it has entered into a technology agreement and collaboration with Mayo Clinic to develop a digital confocal endoscopic laser imaging system for robotic surgery.
The collaboration combines Optiscan's engineering expertise in digital endoscope hardware and software development with Mayo Clinic's expertise in robotic surgery and quality patient care. The agreement covers a 24-month co-development program in which experts from both companies will work together to develop robotic-compatible endoscopic imaging systems, with an initial focus on robotic-assisted breast cancer surgery.
"We are excited to partner with Mayo Clinic to accelerate the development and clinical testing of robotic imaging platforms to accelerate the application of real-time digital pathology and image-guided precision robotic surgery," said Camile Farah, Chief Executive Officer and Managing Director of Optiscan. This collaboration builds on our shared history of innovation and focus on improving healthcare by providing patients with the highest quality outcomes. ”
Mayo Clinic is the world's largest integrated not-for-profit healthcare group dedicated to transforming health care for a healthier world. The institution is committed to providing better medical care and is leading the way in high-quality patient care. Mayo Clinic tops several lists, ranking among the best in many specialties and unmatched in the U.S. medical community. The hospital performs more than 141,000 surgeries and more than 4,000 robotic surgeries each year.
The robotic-assisted surgery market is experiencing significant growth and is expected to continue to expand, driven by factors such as technological advancements, increasing adoption, rising incidence of chronic diseases, aging population, demand for surgeons, and favorable reimbursement policies. The U.S. robotic surgery services market was valued at $1.8 billion in 2022 and is expected to grow at a CAGR of 17.3% to reach $6.4 billion by 2030.
Dr. Farah added, "This collaboration is part of Optiscan's U.S. market expansion strategy, and the platform technology will be embedded as a key part of the intraoperative oncology surgery workflow in various settings and clinical applications, providing surgeons with real-time microscopic information on cancer cell removal to reduce cancer cell omissions and repeat surgeries due to residual disease." ”
Mayo Clinic has a financial interest in the technology referenced in this announcement. Mayo Clinic will use all proceeds to nonprofit efforts such as patient care, education, and research.
This announcement is authorized by the Board of Directors of Optiscan.
About Optiscan:
Optiscan Imaging Ltd (ASX:OIL) is a world leader in the development, manufacture and commercialisation of confocal endoscopic imaging technology for a wide range of medical, translational and preclinical applications. Its technology enables real-time, non-destructive, three-dimensional, in vivo digital imaging at the single-cell level.
The company is committed to the development and application of technologies aimed at providing medical services and researchers with the highest quality real-time microscopy tools to achieve early detection and treatment of diseases, improve patient outcomes, and reduce the high cost of therapeutic drugs and related procedures.
The company's patent-protected proprietary technology uses specially miniaturized components to create a digital microscope the size of a pen tip that can be used on any tissue it touches, generating high-resolution digital pathology images in real time for cancer diagnosis and surgical edge detection. The company's technology development is aimed at diagnosing and treating cancer tumors as early as possible, thereby improving patient outcomes.
To learn more about Optiscan, visit www.optiscan.com or follow us on LinkedIn, X, or Instagram.
To learn more about Mayo Clinic, visit www.mayoclinic.org.
statement
All statements in this announcement, other than statements of historical fact, including, but not limited to, statements regarding the future plans and objectives of Optiscan or any party mentioned herein, are forward-looking statements. Forward-looking statements can be identified by the words "anticipate," "believe," "may," "estimate," "expect," "future," "intend," "may," "opportunity," "plan," "potential," "project," "seek," "will" and other similar expressions that involve risks and uncertainties. These statements are based on an assessment of current economic and operating conditions, as well as assumptions about future events and anticipated actions. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and Optiscan's management, that could cause actual results to differ materially from those expressed or anticipated in these statements.
Disclaimer: The original version of this announcement is the officially authorized version. Translations are provided for convenience only, please refer to the original version, which is the only legally binding version.
View source version press release on businesswire.com: https://www.businesswire.com/news/home/20240513520290/zh-CN/
CONTACT:
For further information, please contact:
Shareholder & General Advice
Optiscan Imaging Ltd
Camile Farah
Phone: +61 3 9538 3333
Mail: [email protected]
Media & Investor Advisory
The Capital Network
Russell Katz
Phone: +61 2 8999 3699
Mail: [email protected]